Rituxan (rituximab) - Roche
Epkinly (epcoritamab-bysp) - Genmab, AbbVie
Brukinsa (zanubrutinib) - BeOne Medicines
Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Epco, Zanu, Ritux for R/R FL or MZL (clinicaltrials.gov) - Sep 26, 2026 - P2 | N=71 | Recruiting | Sponsor: Reid Merryman, MD | N=45 ➔ 71 | Trial completion date: Mar 2030 ➔ Mar 2032 | Trial primary completion date: Mar 2028 ➔ Mar 2030 
Enrollment change • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin's Lymphoma • Oncology
http://clinicaltrials.gov/ct2/show/NCT06563596
 
Sep 26, 2026
 
Prev Next